SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 London Healthcare Conference in London. The live presentation takes place on Wednesday, November 16 at 11:20am GMT ( 3:20amPT/ 6:20amET). The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. About Neurocrine Biosciences Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and INGREZZA (valbenazine or NBI-98854), a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine plans to commercialize INGREZZA in the United States upon approval by the FDA. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.